Mitsubishi UFJ Trust & Banking Corp Cuts Stake in Inspire Medical Systems, Inc. (NYSE:INSP)

Mitsubishi UFJ Trust & Banking Corp lessened its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 11.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 73,352 shares of the company’s stock after selling 9,384 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Inspire Medical Systems were worth $13,598,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its holdings in Inspire Medical Systems by 4.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 281,165 shares of the company’s stock valued at $59,340,000 after purchasing an additional 11,939 shares during the period. Cerity Partners LLC grew its holdings in Inspire Medical Systems by 409.2% during the 3rd quarter. Cerity Partners LLC now owns 13,576 shares of the company’s stock worth $2,865,000 after acquiring an additional 10,910 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Inspire Medical Systems by 99.7% during the third quarter. BNP Paribas Financial Markets now owns 4,711 shares of the company’s stock worth $994,000 after purchasing an additional 2,352 shares in the last quarter. Public Sector Pension Investment Board acquired a new position in shares of Inspire Medical Systems during the 3rd quarter worth about $13,359,000. Finally, Captrust Financial Advisors purchased a new position in Inspire Medical Systems in the third quarter valued at approximately $628,000. Institutional investors and hedge funds own 94.91% of the company’s stock.

Insider Activity at Inspire Medical Systems

In other Inspire Medical Systems news, CTO John Rondoni sold 583 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the transaction, the chief technology officer now owns 10,424 shares in the company, valued at approximately $1,777,187.76. This represents a 5.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Randy Ban sold 25,584 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the sale, the insider now owns 7,259 shares in the company, valued at $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,225 shares of company stock worth $4,806,530 over the last 90 days. Company insiders own 4.10% of the company’s stock.

Inspire Medical Systems Price Performance

Shares of NYSE INSP opened at $156.91 on Friday. The company has a market cap of $4.67 billion, a PE ratio of 90.70, a P/E/G ratio of 2.86 and a beta of 1.48. The stock has a fifty day moving average price of $179.14 and a 200 day moving average price of $190.19. Inspire Medical Systems, Inc. has a 1-year low of $123.00 and a 1-year high of $257.40.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. Analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

INSP has been the topic of several research analyst reports. Wells Fargo & Company cut their price target on shares of Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $260.00 target price on shares of Inspire Medical Systems in a report on Tuesday, February 11th. Robert W. Baird dropped their price target on Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 11th. Truist Financial reduced their price objective on Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating for the company in a research note on Tuesday, February 11th. Finally, Stifel Nicolaus lowered their target price on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a research report on Tuesday, January 21st. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $226.70.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.